JP2002508338A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508338A5
JP2002508338A5 JP2000538720A JP2000538720A JP2002508338A5 JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5 JP 2000538720 A JP2000538720 A JP 2000538720A JP 2000538720 A JP2000538720 A JP 2000538720A JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
composition according
lentivirus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000538720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/025720 external-priority patent/WO1999030742A1/en
Publication of JP2002508338A publication Critical patent/JP2002508338A/ja
Publication of JP2002508338A5 publication Critical patent/JP2002508338A5/ja
Pending legal-status Critical Current

Links

JP2000538720A 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用 Pending JP2002508338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6957997P 1997-12-12 1997-12-12
US60/069,579 1997-12-12
PCT/US1998/025720 WO1999030742A1 (en) 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors

Publications (2)

Publication Number Publication Date
JP2002508338A JP2002508338A (ja) 2002-03-19
JP2002508338A5 true JP2002508338A5 (ru) 2006-01-26

Family

ID=22089926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000538720A Pending JP2002508338A (ja) 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用

Country Status (6)

Country Link
EP (1) EP1037669A4 (ru)
JP (1) JP2002508338A (ru)
KR (1) KR20010033062A (ru)
AU (1) AU749059B2 (ru)
CA (1) CA2314683A1 (ru)
WO (1) WO1999030742A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
ES2276788T3 (es) 2000-05-10 2007-07-01 Sanofi Pasteur Limited Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
EP1616012B1 (en) 2003-04-24 2007-12-19 Fondazione Centro San Raffaele Del Monte Tabor Synthetic bi-directional promoters and uses thereof
JP2011500036A (ja) 2007-10-15 2011-01-06 ザ ユニバーシティー オブ クイーンズランド 構築物系およびその使用
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028565A1 (fr) * 1995-03-16 1996-09-19 Hisamitsu Pharmaceutical Co., Inc. Nouveau recombinant genique
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997020052A1 (en) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
PT871757E (pt) * 1995-11-28 2003-08-29 Univ Johns Hopkins Med Vectores virais condicionalmente replicantes e sua utilizacao
ATE429505T1 (de) * 1996-02-21 2009-05-15 Genetic Immunity Kft Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
US6004799A (en) * 1996-03-05 1999-12-21 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral DNA vaccines
WO1998003669A2 (en) * 1996-07-22 1998-01-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectors for inhibiting hiv and tumor growth
EP0991771A2 (en) * 1997-03-06 2000-04-12 Klaus Überla Lentivirus based vector and vector system
GB9704977D0 (en) * 1997-03-11 1997-04-30 Univ Glasgow FIV vaccine
WO1999004026A2 (en) * 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors

Similar Documents

Publication Publication Date Title
HK1068918A1 (en) A soluble complex comprising a retroviral surface glycoprotein
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
CA2022539A1 (en) Albumin derivatives with therapeutic functions
TR200001553T2 (tr) HIV-1 Tat veya bunun türevleri.
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
EA200200724A1 (ru) Вакцина для профилактической или терапевтической иммунизации против вируса иммунодефицита человека (вич)
CY1112632T1 (el) Αναστολεις ασπαρτυλ πρωτεασης
JP2002508338A5 (ru)
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
EP0225066A3 (en) Antigen determinant peptides and a process for the preparation thereof
WO2000061067A3 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
CA2195125A1 (en) Difluorostatone antiviral agents
WO1996001110A3 (en) Anti-hiv triple combination
JP2002523426A5 (ru)
WO2000018433A3 (en) Use of antigenic complexes of hiv envelope and hla class i antigens as hiv vaccine
WO2004041194A3 (en) Inhibition of hiv-1 replication
FR2647809B1 (fr) Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
JP2007515386A5 (ru)
RU2003125554A (ru) Природные антитела, активные против вируса иммунодефицита человека (вич)
FR2652091B1 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in-vitro des infections dues a ces virus.
WO1999061011A3 (de) Verwendung eines arzneimittels mit einem gehalt an tyrothricin zur behandlung von virusinfektionen
DK0685235T3 (da) Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem
NO963254D0 (no) Makrocykliske difluorstatonderivater som er anvendbare som antivirale midler
RU2003116404A (ru) Штамм вируса западного энцефаломиелита лошадей (western encephalomyelitis virus-wee 163-a) гкв n 964 для приготовления диагностических и профилактических препаратов